Combination bacteriolytic therapy for the treatment of experimental tumors
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Current chemotherapeutic approaches for cancer are in part limited by the inability of drugs to destroy neoplastic cells within poorly vascularized compartments of tumors. We have here systematically assessed anaerobic bacteria for their capacity to grow expansively within avascular compartments of transplanted tumors. Among 26 different strains tested, one ( Clostridium novyi ) appeared particularly promising. We created a strain of C. novyi devoid of its lethal toxin ( C. novyi-NT ) and showed that intravenously injected C. novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed surrounding viable tumor cells. When C. novyi-NT spores were administered together with conventional chemotherapeutic drugs, extensive hemorrhagic necrosis of tumors often developed within 24 h, resulting in significant and prolonged antitumor effects. This strategy, called co mbination ba cterio l ytic t herapy (COBALT), has the potential to add a new dimension to the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,745
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., et al. (1999) · Nature Biotechnology · doi:10.1038/5205 · Cited by 476
Molecular genetics and pathogenesis of Clostridium perfringens
Rood, J. I., & Cole, S. T. (1991) · Microbiological Reviews · doi:10.1128/mmbr.55.4.621-648.1991 · Cited by 450
Clairmont, C., Lee, K. C., Pike, J., Ittensohn, M., Low, K. B., Pawelek, J., Bermudes, D., Brecher, S. M., Margitich, D., Turnier, J., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315497 · Cited by 355
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Malmgren, R. A., & Flanigan, C. (1955) · PubMed · Cited by 263
Yazawa, K., Fujimori, M., Amano, J., Kano, Y., & Taniguchi, S. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700122 · Cited by 241
Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment
Lemmon, M., van Zijl, P., Fox, M., Mauchline, M., Giaccia, A., Minton, N., & Brown, J. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300468 · Cited by 174
Cited by
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
“For propulsion and sensing, bacteria have flagella that enable tissue penetratio”
BackgroundTumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Environmentally Controlled Invasion of Cancer Cells by Engineered Bacteria
Anderson, J. C., Clarke, E. J., Arkin, A. P., & Voigt, C. A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.076 · Cited by 572
Bacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
Zhao, M., Yang, M., Li, X.-M., Jiang, P., Baranov, E., Li, S., Xu, M., Penman, S., & Hoffman, R. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408422102 · Cited by 484
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Yu, Y. A., Shabahang, S., Timiryasova, T. M., Zhang, Q., Beltz, R., Gentschev, I., Goebel, W., & Szalay, A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt937 · Cited by 423
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
“novyi-NT spores, produced as previously described (18, 37), were stereotactically injected into the intracranial tumor using the same coordinates as described above.”
BackgroundMethodInfluentialSelf-citationBacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy
Chen, W., Wang, Y., Qin, M., Zhang, X., Zhang, Z., Sun, X., & Gu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b02235 · Cited by 380
Bioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Tumor hypoxia: A target for selective cancer therapy
Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 352
Bacteria in cancer therapy: a novel experimental strategy
Patyar, S., Joshi, R., Byrav, D. P., Prakash, A., Medhi, B., & Das, B. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-21 · Cited by 340
Gao, S., Li, S., Ma, Z., Liang, S., Shan, T., Zhang, M., Zhu, X., Zhang, P., Liu, G., Zhou, F., et al. (2016) · Infectious Agents and Cancer · doi:10.1186/s13027-016-0049-x · Cited by 321
Local bacteria affect the efficacy of chemotherapeutic drugs
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., Urbaniak, C., Byrne, W. L., & Tangney, M. (2015) · Scientific Reports · doi:10.1038/srep14554 · Cited by 313
Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
Sedighi, M., Zahedi Bialvaei, A., Hamblin, M. R., Ohadi, E., Asadi, A., Halajzadeh, M., Lohrasbi, V., Mohammadzadeh, N., Amiriani, T., Krutova, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2148 · Cited by 308
Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., & Hoffman, R. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0716 · Cited by 305
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Self-citationBacteria as tumour-targeting vectors
Pawelek, J. M., Low, K. B., & Bermudes, D. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01194-x · Cited by 290
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Ultrasound-controllable engineered bacteria for cancer immunotherapy
Abedi, M. H., Yao, M. S., Mittelstein, D. R., Bar-Zion, A., Swift, M. B., Lee-Gosselin, A., Barturen-Larrea, P., Buss, M. T., & Shapiro, M. G. (2022) · Nature Communications · doi:10.1038/s41467-022-29065-2 · Cited by 260
Bacteria-Mediated Hypoxia-Specific Delivery of Nanoparticles for Tumors Imaging and Therapy
Luo, C.-H., Huang, C.-T., Su, C.-H., & Yeh, C.-S. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00262 · Cited by 256
Targeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Stritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., & Szalay, A. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.01.008 · Cited by 224
Bacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
Kramer, M. G., Masner, M., Ferreira, F. A., & Hoffman, R. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00016 · Cited by 145
Bacteriocins: Perspective for the development of novel anticancer drugs
Baindara, P., Korpole, S., & Grover, V. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9420-8 · Cited by 139
Clostridium spores as anti-tumour agents
Van Mellaert, L., Barbé, S., & Anné, J. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.02.002 · Cited by 101
Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models
Lee, C., Wu, C., & Shiau, A. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.626 · Cited by 93
“[35] reported that dolastatin, a vascular collapsing agent, enhanced the ability of Clostridium novyi spores to lyse tumors.”
BackgroundTumor vascular infarction: prospects and challenges
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-016-2171-3 · Cited by 88
Technical guide for genetic advancement of underdeveloped and intractable Clostridium
Pyne, M. E., Bruder, M., Moo-Young, M., Chung, D. A., & Chou, C. P. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.04.003 · Cited by 78
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
The Development of Live Microorganism-Based Oxygen Shuttles for Enhanced Hypoxic Tumor Therapy
Han, D., Zhang, X., Ma, Y., Yang, X., & Li, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100517 · Cited by 25
“Among the existing targeted therapies, bacterial therapy has been used for more than a century [43,44].”
BackgroundDo Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?
Dicks, L. M. T., & Vermeulen, W. (2022) · Microorganisms · doi:10.3390/microorganisms10091733 · Cited by 25
“Clostridium novyi, made non-pathogenic by deleting the gene encoding α-toxin NT, destroyed tumours and secreted liposomase [60].”
Background
Metadata
- Authors
- Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-11-27
- Volume
- 98
- Issue
- 26
- Pages
- 15155-15160
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2046894146
- Cited by
- 563
- References
- 26
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.